ML20216C919: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot insert)
 
(StriderTol Bot change)
 
Line 20: Line 20:
{{#Wiki_filter:.
{{#Wiki_filter:.
l Sk 19 E 4 I- >
l Sk 19 E 4 I- >
From: Torre M. Taylor (TMT)                                                                 l O(,/
From: Torre M. Taylor (TMT)
To:   _
O(,/
DAC. W
To:
* L , b,8 l
DAC.
Date: Wednesday, October 12,1994 3:33 pm                                                   j
W
          & Seddectiv.'SACMUI       Meeting l
* L, b,8 Date: Wednesday, October 12,1994 3:33 pm j
                                    .m ni Dr. Glenn wanted me to contact you to see if you, or a member of your staff, would like to make the presentation to the ACMUI, Nov. 18,1994, on the Patient Release Criteria.       l The status and issues need to be addressed. Also, the individual needs to be prepared for a " working discussion" of the criteria - to discuss specific issues on which the Committee has comments.
Seddectiv SACMUI Meeting l
            ~ The session begins on Nov.18 from 8:00 - 10:00 a.m. The meeting is in TWFN, T2B3.
.m ni Dr. Glenn wanted me to contact you to see if you, or a member of your staff, would like to make the presentation to the ACMUI, Nov. 18,1994, on the Patient Release Criteria.
The status and issues need to be addressed. Also, the individual needs to be prepared for a " working discussion" of the criteria - to discuss specific issues on which the Committee has comments.
~ The session begins on Nov.18 from 8:00 - 10:00 a.m. The meeting is in TWFN, T2B3.
The meeting itselfis on Thursday from 8:00 to 5:00 and on Friday from 8:00 to 1:00. I will forward an agenda once I know who will be making all presentations.
The meeting itselfis on Thursday from 8:00 to 5:00 and on Friday from 8:00 to 1:00. I will forward an agenda once I know who will be making all presentations.
    .        eIf possible, I need a brief summary for the briefing book., However, we need to get the book to reproduction by' Mon. or Tues; next' week, s'o I! understand if you can't get something to me by then. If not, I'll put a short statement as to presentation on status / issues.
eIf possible, I need a brief summary for the briefing book., However, we need to get the book to reproduction by' Mon. or Tues; next' week, s' I! understand if you can't get o
I am cc'ing this message to Kitty since you are out ill.     # g WGN l
something to me by then. If not, I'll put a short statement as to presentation on status / issues.
Thanks, Torre (504-1062, TMT) fs                                                                                                       i
I am cc'ing this message to Kitty since you are out ill.
  'k>         CC:             KSD l
# g WGN Thanks, Torre (504-1062, TMT) i fs
l l
'k>
V 9804150103 980402 PDR       PR 20   62FR4120         PDR                                                                   .
CC:
L
KSD V
      .~ ,iav/v"                                                                                         ;
9804150103 980402 PDR PR 20 62FR4120 PDR L
.~,iav/v"


i                           '                      >-
V i
V (n, M ,V, !
/
      .          /                                                            M, i H                   -
(n, M,V, !
51458                   Federal Register / Vol. 59, No.195 / Tuesday, October 11, 1994 / Notices g    8. An Indication whether Section         the study of the ved; cal use program by members, NRC consultants, and NRC                     ,
M, i H
j504(h) Public Law 96-511 applies:             the National Acade ry of Science;(4)           staff will be permitted at the discretion
51458 Federal Register / Vol. 59, No.195 / Tuesday, October 11, 1994 / Notices
        ' Applicable.                                   brachytherapy fracti,m. !on issum : {5)         of the Chairman.
: 8. An Indication whether Section the study of the ved; cal use program by members, NRC consultants, and NRC gj504(h) Public Law 96-511 applies:
: 9. Abstract:In response to a petition     Abnonnal Occurrence Criter                           4. The transcript, minutes of the for rulemaking submitted by the                 % i in3, ,r,) rulemaking -         ' iease of meeting, and writte.i . m i.wr i . u " ' c           I American College of Nuclear Phys.cuns Patients Contaming                                       available for inspecd.it., and u p)i%             .
the National Acade ry of Science;(4) staff will be permitted at the discretion
and the Society of Nuclear Medicine,                    h                                    for a fee, at the NRC Public De nm' Udir1 vnar      oticals or Permanent            Room,2120 L Street NW., Lor or b , -1.
' Applicable.
the NRC is amending its regulations for       Implants 10 CFR 3' 73";(7) discussion                                                           l the medical use of byproduct material          ot t - # Notica 'f P oposed                     Washington, DC 20555, on or al,' a             g Thu rule is necessary to provide greater Rum.miing fur 10 M Pact . ,; (d,                     December 9,1994.
brachytherapy fracti,m. !on issum : {5) of the Chairman.
flexibility by eliminating current             issues involving misuministrations-                 5. Seating for the public will be on a       ;
: 9. Abstract:In response to a petition Abnonnal Occurrence Criter
regulatory restrictions and allowing           follow up of patiem , NRC use of                 fir,st-come, first served basis.
: 4. The transcript, minutes of the for rulemaking submitted by the
This meetmg will be held in properly qualified nuclear pharmacists - consultants; (9) review and approval of                               ,
% i in3,,r,) rulemaking -
accordance with the Atomic Energy Au and authorized users who are                   the bylaws for the Committee; and (10) of 1954, as amended (primarily Section physicians greater discretion in               report on the Commission briefing held on October 20,1994.                            161al: the Federal Advisory Committee preparing radioactive drugs containing byproduct material for medical use.           DATES:The meeting will being 8 a m. on
' iease of meeting, and writte.i. m i.wr i. u " ' c American College of Nuclear Phys.cuns Patients Contaming available for inspecd.it., and u p)i%
                                                                                                          .w D MC. App.); and th,e m ss n,s quMmns m M m.
Udir1 vnar oticals or Permanent for a fee, at the NRC Public De nm' and the Society of Nuclear Medicine, h
This rule will also allow the use of           November 17 and 18 1994                                                 "          "
the NRC is amending its regulations for Implants 10 CFR 3' 73";(7) discussion Room,2120 L Street NW., Lor or b, -1.
byproduct materialin both research             ADDRESSES: U.S. Nuclear Regulatory                 Dated. Oct ber 4,1994.
l ot t - # Notica 'f P oposed Washington, DC 20555, on or al,' a g
involving human subjects and the .             Commission Two White Flint North, medical use of rediolabeled biologics. In Room T283,11545 Rockville Pike.                       Andrew L. Bates, eddition, this rule also contams other         Rockville, MD.                                 Adusory committee Management offu cr.
the medical use of byproduct material Thu rule is necessary to provide greater Rum.miing fur 10 M Pact.,; (d, December 9,1994.
flexibility by eliminating current issues involving misuministrations-
: 5. Seating for the public will be on a regulatory restrictions and allowing follow up of patiem, NRC use of fir,st-come, first served basis.
properly qualified nuclear pharmacists - consultants; (9) review and approval of This meetmg will be held in and authorized users who are the bylaws for the Committee; and (10) accordance with the Atomic Energy Au physicians greater discretion in report on the Commission briefing held of 1954, as amended (primarily Section 161al: the Federal Advisory Committee preparing radioactive drugs containing on October 20,1994.
.w D MC. App.); and th,e byproduct material for medical use.
DATES:The meeting will being 8 a m. on m ss n,s quMmns m M m.
This rule will also allow the use of November 17 and 18 1994 byproduct materialin both research ADDRESSES: U.S. Nuclear Regulatory Dated. Oct ber 4,1994.
involving human subjects and the.
Commission Two White Flint North, medical use of rediolabeled biologics. In Room T283,11545 Rockville Pike.
Andrew L. Bates, eddition, this rule also contams other Rockville, MD.
Adusory committee Management offu cr.
miscellaneous and conforming IFR Doc. 94-25033 Filed 10-7-94; 8.4 s aml FOR FURTHER INFORMATtON CONTACT:
miscellaneous and conforming IFR Doc. 94-25033 Filed 10-7-94; 8.4 s aml FOR FURTHER INFORMATtON CONTACT:
amendments necessary to clarify or             Larry W. Camper, Office of Nuclear             stumo coor neo-esw Material Safety and Safeguards MS Co e of         ubrn a a) be             'I 8FS, U.S. Nuclear, Regulatory inspected or obtained for a fee from the                                n n DC 20555, NRC Public Document Room 2120 L Street NW (Lower Levell. Washington.
amendments necessary to clarify or Larry W. Camper, Office of Nuclear stumo coor neo-esw Material Safety and Safeguards MS Co e of ubrn a a) be inspected or obtained for a fee from the
                                                              "l ye              5-    -
'I 8FS, U.S. Nuclear, Regulatory n n DC 20555, NRC Public Document Room 2120 L "l ye p
p DC.                                           Conduct of the Meeting                           Meeting of the President's Committee Comments and questions can be                                                             of Advisors on Science and Barry Siegel, M.D. will chair the directed by mail to the OMB reviewer:                                                           Technology meeting. Dr. Siegel will conduct the meeting in a manner that will facilitate         ACTION: Notice of meeting.
5-Street NW (Lower Levell. Washington.
lat   dr (315           01,     0, t 0 e                             "
DC.
Q/and -0120), NEOB-10202, Office of                      g }9 n            d      $" "to       Ic    
Conduct of the Meeting Meeting of the President's Committee of Advisors on Science and Comments and questions can be Barry Siegel, M.D. will chair the directed by mail to the OMB reviewer:
meeting. Dr. Siegel will conduct the Technology meeting in a manner that will facilitate ACTION: Notice of meeting.
lat dr (315 01, 0,
t 0 e
$" "to Ic


==SUMMARY==
==SUMMARY==
:This notice sets forth the Management and Budget. Washm, gton,           participation in the meeting:                   schedule and proposed agenda for the DC 20503.                                         1. Persons who wish to provide a             first meeting of the President's Comments can also be submitted by                                                         Committee of Advisors on Science and written statement should submit a Technology (PCAST), and describes the N C Clea ce Of c is Brenda f* Producible copy to Larry W. Camper                     functions of the Committee. Notice of (address listed above). Comments must J. Shelton' (301) 415-7233~                     be received by November 10,1994, in             this meeting is required under the Dated at Rockville Maryland. this 29th day order to ensure consideration at the             Federal Advisory Committee Act.
:This notice sets forth the Q/and -0120), NEOB-10202, Office of g }9 n d
I September 1994.                           meeting. The transcript of the meeting         DATES AND PLACE: October 25 and 26.
Management and Budget. Washm, gton, participation in the meeting:
For the Nuclear Regulatory Commasinn'     w 11 be kept open until November 28.             t 994. The White llouse Conference Gerald F.Cranford,                             1994, for inclusion of written                 Center. Truman Room, Third Floor. 726 Designated Senior Official for Inform 9tmn     comments.                                       bckson Place NW, Washington, DC Resources Management-                             2. Persons who wish to make oral             20500.
schedule and proposed agenda for the DC 20503.
IFR Doc. 94-25032 Filed to-7-94 a 45 ami       statements should inform Mr. Camper.           TYPE OF MEETING:Open.
: 1. Persons who wish to provide a first meeting of the President's Comments can also be submitted by written statement should submit a Committee of Advisors on Science and N C Clea ce Of c is Brenda f* Producible copy to Larry W. Camper Technology (PCAST), and describes the functions of the Committee. Notice of (address listed above). Comments must J. Shelton' (301) 415-7233~
a:Luwo coot rson.et*                           in writing, by November 3,1994.                 PROPOSED SCHEDULE AND AGENDA:The Statements must pertain to the topics on President's Committee of Advisors on the agenda for the meeting The                   Science and Technology (PCAST) will Advisory Committee on Medical Uses             Chairman will rule on requests to make           meet in open session on Tuesday, of Isotepes: Meeting Notice                   oral statements. Members of the public           October 25,1994, at approximately 9 00 AcENCY: W ! ear Regulatory                     will be permitted   to make   oral             AM to be briefed on current activities of statements   if time permits. Pennission       the Office of Science and Tec.hnology Commimen.                                      to make oral statements will be based on Pohcy (OSTP). This session will end at ACTION: Nmu e of meeting.
be received by November 10,1994, in this meeting is required under the Dated at Rockville Maryland. this 29th day order to ensure consideration at the Federal Advisory Committee Act.
the order in which requests are                 approximately 12 00 Noon. The supua$vhe U.S. Nuclear Regulatory               received. In general, oral statements will Committee will reconvene in open be limited to approximately 5 minutes.         session at approximately 1:30 PM to             j Commission will convene its next regular meeting of the Advisory               Oral statements must be supplemented           discuss possible long-term agenda items         i Committee on Medical Uses of isotopes by detailed written statements, for the                   for the next year. This session will end (ACMUI) on November 17 and 18,1994. record. Rulings on who may speak, the                       at approximately 5:00 PM. Either of             l Topics of discussion will include: (1)         order of presentation, and time                 these sessions may be interrupted for Rulemaking on " Preparation. Transfer,         allotments may be obtained by calling           the PCAST to gather at the White llouse and Use of Byproduct Material for             Mr. Camper. 301-415-7269, between 9             to be introduced to the President of the Medical Use";(2) status of                     a.m. and 5 EST, on November 14,1994.             United States.
I September 1994.
implementation of the Quality                     3. At the meeting, questions from               The Committee will meet again in Management rule: (3) progress report on attendees other than committee                         open session on Wednesday, October
meeting. The transcript of the meeting DATES AND PLACE: October 25 and 26.
t 994. The White llouse Conference For the Nuclear Regulatory Commasinn' w 11 be kept open until November 28.
Gerald F.Cranford, 1994, for inclusion of written Center. Truman Room, Third Floor. 726 bckson Place NW, Washington, DC Designated Senior Official for Inform 9tmn comments.
Resources Management-
: 2. Persons who wish to make oral 20500.
IFR Doc. 94-25032 Filed to-7-94 a 45 ami statements should inform Mr. Camper.
TYPE OF MEETING:Open.
a:Luwo coot rson.et*
in writing, by November 3,1994.
PROPOSED SCHEDULE AND AGENDA:The Statements must pertain to the topics on President's Committee of Advisors on the agenda for the meeting The Science and Technology (PCAST) will Advisory Committee on Medical Uses Chairman will rule on requests to make meet in open session on Tuesday, of Isotepes: Meeting Notice oral statements. Members of the public October 25,1994, at approximately 9 00 AcENCY: W ! ear Regulatory will be permitted to make oral AM to be briefed on current activities of Commimen.
statements if time permits. Pennission the Office of Science and Tec.hnology to make oral statements will be based on Pohcy (OSTP). This session will end at ACTION: Nmu e of meeting.
the order in which requests are approximately 12 00 Noon. The supua$vhe U.S. Nuclear Regulatory received. In general, oral statements will Committee will reconvene in open Commission will convene its next be limited to approximately 5 minutes.
session at approximately 1:30 PM to j
regular meeting of the Advisory Oral statements must be supplemented discuss possible long-term agenda items i
Committee on Medical Uses of isotopes by detailed written statements, for the for the next year. This session will end (ACMUI) on November 17 and 18,1994. record. Rulings on who may speak, the at approximately 5:00 PM. Either of Topics of discussion will include: (1) order of presentation, and time these sessions may be interrupted for Rulemaking on " Preparation. Transfer, allotments may be obtained by calling the PCAST to gather at the White llouse and Use of Byproduct Material for Mr. Camper. 301-415-7269, between 9 to be introduced to the President of the Medical Use";(2) status of a.m. and 5 EST, on November 14,1994.
United States.
implementation of the Quality
: 3. At the meeting, questions from The Committee will meet again in Management rule: (3) progress report on attendees other than committee open session on Wednesday, October


a SuNm aa-y pop _ ACnun                                         i O
a SuNm aa-y pop _ ACnun i
t                          RULEMAKING ON PATIENT RELEASE CRITERIA, Status:         Proposed rule published June 15,1994 (59 FR 30724). Comment period for the proposed rule, draft regulatory guide, NUREG-1492 expired August 29,1994. 58 comments were received.
O t
RULEMAKING ON PATIENT RELEASE CRITERIA, Status:
Proposed rule published June 15,1994 (59 FR 30724). Comment period for the proposed rule, draft regulatory guide, NUREG-1492 expired August 29,1994. 58 comments were received.
Midor Issues:
Midor Issues:
: 1.     Exclusion of patient release from 10 CFR 20.1301(a):
1.
Almost all commenters approved deletion from Part 20
Exclusion of patient release from 10 CFR 20.1301(a):
: 2.     Activity-based vs. dose-base release limit:
Almost all commenters approved deletion from Part 20 2.
A majority of commenters approved of the 500 mrem dose limit. A number of commenters preferred maintaining the status quo of 10 CFR 35.75. Some               ,
Activity-based vs. dose-base release limit:
commenters were concerned that a dose-based limit would cause confusion and potential problems. A few commenters said that a calculational approach requires the doctor to ask many personal questions. One commenter said dose         ;
A majority of commenters approved of the 500 mrem dose limit. A number of commenters preferred maintaining the status quo of 10 CFR 35.75. Some commenters were concerned that a dose-based limit would cause confusion and potential problems. A few commenters said that a calculational approach requires the doctor to ask many personal questions. One commenter said dose estimates would be inaccurate because there is no reliable method of predicting the time and proximity to others. Some commenters were concerned about increased cost of treatment due to calculations and recordkeeping. Some
estimates would be inaccurate because there is no reliable method of predicting the time and proximity to others. Some commenters were concerned about increased cost of treatment due to calculations and recordkeeping. Some
(
(             commenters said that there probably would be no significant decrease in radiation exposure.
commenters said that there probably would be no significant decrease in radiation exposure.
: 3. Release quantities Some commenters did not think release should be permitted with quantities > 30 mci.
3.
: 4. Recordkeeping (summing dose) for administrations > 0.1 rem                           i i
Release quantities Some commenters did not think release should be permitted with quantities > 30 mci.
This issue generated the strongest opposition to the proposed rule. Many             4 I
4.
commenters said the requirement would cause excessive costs in time, effort, and money to find previous administration records and that the NRC underestimated the cost of record generation.
Recordkeeping (summing dose) for administrations > 0.1 rem i
: 5.     Written instructions to patients Many commenters said that instructions do not need to be written and that oral instructions alone should be permissible. However, a major health maintenance organization strongly supported the requirement that the instructions be written.
i This issue generated the strongest opposition to the proposed rule. Many 4
I commenters said the requirement would cause excessive costs in time, effort, and money to find previous administration records and that the NRC underestimated the cost of record generation.
5.
Written instructions to patients Many commenters said that instructions do not need to be written and that oral instructions alone should be permissible. However, a major health maintenance organization strongly supported the requirement that the instructions be written.
Several commenters said that a sizable fraction of patients will not behave as instructed.
Several commenters said that a sizable fraction of patients will not behave as instructed.
C
,C
                                                                                                  ;}}
;}}

Latest revision as of 20:46, 3 December 2024

Informs That Dr Glenn Wanted to Know If Recipient or Member of Staff Would Like to Make Presentation to ACMUI,941118 on Patient Release Criteria
ML20216C919
Person / Time
Issue date: 10/12/1994
From: Thomas Taylor
NRC
To: Cool D
NRC
Shared Package
ML20013H248 List:
References
FRN-62FR4120, RULE-PR-20, RULE-PR-35 AE41-2-083, AE41-2-83, NUDOCS 9804150103
Download: ML20216C919 (3)


Text

.

l Sk 19 E 4 I- >

From: Torre M. Taylor (TMT)

O(,/

To:

DAC.

W

  • L, b,8 Date: Wednesday, October 12,1994 3:33 pm j

Seddectiv SACMUI Meeting l

.m ni Dr. Glenn wanted me to contact you to see if you, or a member of your staff, would like to make the presentation to the ACMUI, Nov. 18,1994, on the Patient Release Criteria.

The status and issues need to be addressed. Also, the individual needs to be prepared for a " working discussion" of the criteria - to discuss specific issues on which the Committee has comments.

~ The session begins on Nov.18 from 8:00 - 10:00 a.m. The meeting is in TWFN, T2B3.

The meeting itselfis on Thursday from 8:00 to 5:00 and on Friday from 8:00 to 1:00. I will forward an agenda once I know who will be making all presentations.

eIf possible, I need a brief summary for the briefing book., However, we need to get the book to reproduction by' Mon. or Tues; next' week, s' I! understand if you can't get o

something to me by then. If not, I'll put a short statement as to presentation on status / issues.

I am cc'ing this message to Kitty since you are out ill.

  1. g WGN Thanks, Torre (504-1062, TMT) i fs

'k>

CC:

KSD V

9804150103 980402 PDR PR 20 62FR4120 PDR L

.~,iav/v"

V i

/

(n, M,V, !

M, i H

51458 Federal Register / Vol. 59, No.195 / Tuesday, October 11, 1994 / Notices

8. An Indication whether Section the study of the ved; cal use program by members, NRC consultants, and NRC gj504(h) Public Law 96-511 applies:

the National Acade ry of Science;(4) staff will be permitted at the discretion

' Applicable.

brachytherapy fracti,m. !on issum : {5) of the Chairman.

9. Abstract:In response to a petition Abnonnal Occurrence Criter
4. The transcript, minutes of the for rulemaking submitted by the

% i in3,,r,) rulemaking -

' iease of meeting, and writte.i. m i.wr i. u " ' c American College of Nuclear Phys.cuns Patients Contaming available for inspecd.it., and u p)i%

Udir1 vnar oticals or Permanent for a fee, at the NRC Public De nm' and the Society of Nuclear Medicine, h

the NRC is amending its regulations for Implants 10 CFR 3' 73";(7) discussion Room,2120 L Street NW., Lor or b, -1.

l ot t - # Notica 'f P oposed Washington, DC 20555, on or al,' a g

the medical use of byproduct material Thu rule is necessary to provide greater Rum.miing fur 10 M Pact.,; (d, December 9,1994.

flexibility by eliminating current issues involving misuministrations-

5. Seating for the public will be on a regulatory restrictions and allowing follow up of patiem, NRC use of fir,st-come, first served basis.

properly qualified nuclear pharmacists - consultants; (9) review and approval of This meetmg will be held in and authorized users who are the bylaws for the Committee; and (10) accordance with the Atomic Energy Au physicians greater discretion in report on the Commission briefing held of 1954, as amended (primarily Section 161al: the Federal Advisory Committee preparing radioactive drugs containing on October 20,1994.

.w D MC. App.); and th,e byproduct material for medical use.

DATES:The meeting will being 8 a m. on m ss n,s quMmns m M m.

This rule will also allow the use of November 17 and 18 1994 byproduct materialin both research ADDRESSES: U.S. Nuclear Regulatory Dated. Oct ber 4,1994.

involving human subjects and the.

Commission Two White Flint North, medical use of rediolabeled biologics. In Room T283,11545 Rockville Pike.

Andrew L. Bates, eddition, this rule also contams other Rockville, MD.

Adusory committee Management offu cr.

miscellaneous and conforming IFR Doc. 94-25033 Filed 10-7-94; 8.4 s aml FOR FURTHER INFORMATtON CONTACT:

amendments necessary to clarify or Larry W. Camper, Office of Nuclear stumo coor neo-esw Material Safety and Safeguards MS Co e of ubrn a a) be inspected or obtained for a fee from the

'I 8FS, U.S. Nuclear, Regulatory n n DC 20555, NRC Public Document Room 2120 L "l ye p

5-Street NW (Lower Levell. Washington.

DC.

Conduct of the Meeting Meeting of the President's Committee of Advisors on Science and Comments and questions can be Barry Siegel, M.D. will chair the directed by mail to the OMB reviewer:

meeting. Dr. Siegel will conduct the Technology meeting in a manner that will facilitate ACTION: Notice of meeting.

lat dr (315 01, 0,

t 0 e

$" "to Ic

SUMMARY

This notice sets forth the Q/and -0120), NEOB-10202, Office of g }9 n d

Management and Budget. Washm, gton, participation in the meeting:

schedule and proposed agenda for the DC 20503.

1. Persons who wish to provide a first meeting of the President's Comments can also be submitted by written statement should submit a Committee of Advisors on Science and N C Clea ce Of c is Brenda f* Producible copy to Larry W. Camper Technology (PCAST), and describes the functions of the Committee. Notice of (address listed above). Comments must J. Shelton' (301) 415-7233~

be received by November 10,1994, in this meeting is required under the Dated at Rockville Maryland. this 29th day order to ensure consideration at the Federal Advisory Committee Act.

I September 1994.

meeting. The transcript of the meeting DATES AND PLACE: October 25 and 26.

t 994. The White llouse Conference For the Nuclear Regulatory Commasinn' w 11 be kept open until November 28.

Gerald F.Cranford, 1994, for inclusion of written Center. Truman Room, Third Floor. 726 bckson Place NW, Washington, DC Designated Senior Official for Inform 9tmn comments.

Resources Management-

2. Persons who wish to make oral 20500.

IFR Doc. 94-25032 Filed to-7-94 a 45 ami statements should inform Mr. Camper.

TYPE OF MEETING:Open.

a:Luwo coot rson.et*

in writing, by November 3,1994.

PROPOSED SCHEDULE AND AGENDA:The Statements must pertain to the topics on President's Committee of Advisors on the agenda for the meeting The Science and Technology (PCAST) will Advisory Committee on Medical Uses Chairman will rule on requests to make meet in open session on Tuesday, of Isotepes: Meeting Notice oral statements. Members of the public October 25,1994, at approximately 9 00 AcENCY: W ! ear Regulatory will be permitted to make oral AM to be briefed on current activities of Commimen.

statements if time permits. Pennission the Office of Science and Tec.hnology to make oral statements will be based on Pohcy (OSTP). This session will end at ACTION: Nmu e of meeting.

the order in which requests are approximately 12 00 Noon. The supua$vhe U.S. Nuclear Regulatory received. In general, oral statements will Committee will reconvene in open Commission will convene its next be limited to approximately 5 minutes.

session at approximately 1:30 PM to j

regular meeting of the Advisory Oral statements must be supplemented discuss possible long-term agenda items i

Committee on Medical Uses of isotopes by detailed written statements, for the for the next year. This session will end (ACMUI) on November 17 and 18,1994. record. Rulings on who may speak, the at approximately 5:00 PM. Either of Topics of discussion will include: (1) order of presentation, and time these sessions may be interrupted for Rulemaking on " Preparation. Transfer, allotments may be obtained by calling the PCAST to gather at the White llouse and Use of Byproduct Material for Mr. Camper. 301-415-7269, between 9 to be introduced to the President of the Medical Use";(2) status of a.m. and 5 EST, on November 14,1994.

United States.

implementation of the Quality

3. At the meeting, questions from The Committee will meet again in Management rule: (3) progress report on attendees other than committee open session on Wednesday, October

a SuNm aa-y pop _ ACnun i

O t

RULEMAKING ON PATIENT RELEASE CRITERIA, Status:

Proposed rule published June 15,1994 (59 FR 30724). Comment period for the proposed rule, draft regulatory guide, NUREG-1492 expired August 29,1994. 58 comments were received.

Midor Issues:

1.

Exclusion of patient release from 10 CFR 20.1301(a):

Almost all commenters approved deletion from Part 20 2.

Activity-based vs. dose-base release limit:

A majority of commenters approved of the 500 mrem dose limit. A number of commenters preferred maintaining the status quo of 10 CFR 35.75. Some commenters were concerned that a dose-based limit would cause confusion and potential problems. A few commenters said that a calculational approach requires the doctor to ask many personal questions. One commenter said dose estimates would be inaccurate because there is no reliable method of predicting the time and proximity to others. Some commenters were concerned about increased cost of treatment due to calculations and recordkeeping. Some

(

commenters said that there probably would be no significant decrease in radiation exposure.

3.

Release quantities Some commenters did not think release should be permitted with quantities > 30 mci.

4.

Recordkeeping (summing dose) for administrations > 0.1 rem i

i This issue generated the strongest opposition to the proposed rule. Many 4

I commenters said the requirement would cause excessive costs in time, effort, and money to find previous administration records and that the NRC underestimated the cost of record generation.

5.

Written instructions to patients Many commenters said that instructions do not need to be written and that oral instructions alone should be permissible. However, a major health maintenance organization strongly supported the requirement that the instructions be written.

Several commenters said that a sizable fraction of patients will not behave as instructed.

,C